Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.

Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R; GALA Study Group.

Ann Neurol. 2013 Jun;73(6):705-13. doi: 10.1002/ana.23938. Epub 2013 Jun 28.

PMID:
23686821
2.

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M; 9006 Study Group.

Neurology. 2007 Mar 20;68(12):939-44.

PMID:
17372130
4.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
5.

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group.

Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11.

PMID:
18789766
6.

GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.

Wolinsky JS, Borresen TE, Dietrich DW, Wynn D, Sidi Y, Steinerman JR, Knappertz V, Kolodny S; GLACIER Study Group.

Mult Scler Relat Disord. 2015 Jul;4(4):370-6. doi: 10.1016/j.msard.2015.06.005. Epub 2015 Jun 14.

7.

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.

Johnson KP, Ford CC, Lisak RP, Wolinsky JS.

Acta Neurol Scand. 2005 Jan;111(1):42-7.

PMID:
15595937
8.

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.

Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW; GA/minocycline study investigators.

Mult Scler. 2009 Oct;15(10):1183-94. doi: 10.1177/1352458509106779. Epub 2009 Sep 23.

PMID:
19776092
9.

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.

Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL.

Mult Scler. 2008 Jun;14(5):663-70. doi: 10.1177/1352458507085759. Epub 2008 Apr 18.

PMID:
18424479
10.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1087-97. Erratum in: N Engl J Med. 2012 Oct 25;367(17):1673.

11.

Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.

Sanford M, Lyseng-Williamson KA.

Drugs. 2011 Oct 1;71(14):1865-91. doi: 10.2165/11207540-000000000-00000. Review.

PMID:
21942977
12.
13.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
14.

Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.

Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.

Clin Ther. 2010 Jun;32(6):1061-6. doi: 10.1016/j.clinthera.2010.06.005.

PMID:
20637960
15.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
16.

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Simpson D, Noble S, Perry C.

CNS Drugs. 2002;16(12):825-50. Review.

PMID:
12421116
17.
19.

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.

Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M; European/Canadian Glatiramer Acetate Study Group.

Brain. 2001 Sep;124(Pt 9):1803-12.

PMID:
11522582
20.

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.

Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20.

PMID:
20488825

Supplemental Content

Support Center